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Objectives: The characterization of Giardia lamblia WB C6 strains resistant to metronidazole and to the
nitro-thiazole nitazoxanide [2-acetolyloxy-N-(5-nitro 2-thiazolyl) benzamide] as the parent compound of
thiazolides, a novel class of anti-infective drugs with a broad spectrum of activities against a wide
variety of helminths, protozoa and enteric bacteria.
Methods: Issuing from G. lamblia WB C6, we have generated two strains exhibiting resistance to nita-
zoxanide (strain C4) and to metronidazole (strain C5) and determined their susceptibilities to both
drugs. Using quantitative RT–PCR, we have analysed the expression of genes that are potentially
involved in resistance formation, namely genes encoding pyruvate oxidoreductases (POR1 and POR2),
nitroreductase (NR), protein disulphide isomerases (PDI2 and PDI4) and variant surface proteins
(VSPs; TSA417). We have cloned and expressed PDI2 and PDI4 in Escherichia coli. Using an enzyme
assay based on the polymerization of insulin, we have determined the activities of both enzymes in the
presence and absence of nitazoxanide.
Results: Whereas C4 was cross-resistant to nitazoxanide and to metronidazole, C5 was resistant only
to metronidazole. Transcript levels of the potential targets for nitro-drugs POR1, POR2 and NR were
only slightly modified, PDI2 transcript levels were increased in both resistant strains and PDI4 levels in
C4. This correlated with the findings that the functional activities of recombinant PDI2 and PDI4 were
inhibited by nitazoxanide. Moreover, drastic changes were observed in VSP gene expression.
Conclusions: These results suggest that resistance formation in Giardia against nitazoxanide and
metronidazole is linked, and possibly mediated by, altered gene expression in drug-resistant strains
compared with non-resistant strains of Giardia.
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Introduction
Giardia lamblia (syn. G. duodenalis; G. intestinalis), a flagel-
lated protozoan, is the most common causative agent of persist-
ent diarrhoea worldwide. The life cycle includes motile,
flagellated trophozoites parasitizing the upper intestine, and
thick-walled cysts forming in the lower intestine that are shed
with the faeces.1 Antigiardial chemotherapy is directed against
the trophozoites. In the past, various antiparasitic drugs have
been developed but only a few turned out to be effective for
treatment of giardiasis.
Since the late 1950s, metronidazole (commercially known as
Flagylw) and other nitroimidazoles have been used as therapy
of choice against giardiasis.2,3 Metronidazole efficiently enters
giardial trophozoites and is supposed to be ‘activated’ via redox
mechanisms involving reduction of the nitro group by the meta-
bolic anaerobic enzyme pyruvate:ferredoxin oxidoreductase,
PFOR or POR, during the decarboxylation of pyruvate.4
Reduced metronidazole then binds covalently to DNA, and the
resulting damage leads to subsequent death of the parasite.
Although metronidazole and other nitroimidazoles are able to
efficiently kill Giardia trophozoites, treatment of giardiasis with
these drugs is often associated with recurrence of symptoms.5
Furthermore, drug resistance is one of the reasons for treatment
failure, but it is difficult to discriminate between ‘cure followed
by reinfection’ and other effects such as lactose intolerance.
Resistance to metronidazole and other nitroimidazoles has
mostly been demonstrated or induced in vitro. However, various
genotypically distinct isolates with reduced drug susceptibility
have also been found in human patients.2,6 Formation of giardial
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resistance to metronidazole seems to be associated with down-
regulation of POR activity.3 This is consistent with the involve-
ment of POR in metronidazole activation.7
The situation in antigiardial chemotherapy changed in the
middle of the 1990s, when a new antiparasitic agent, nitazoxa-
nide (commercially known as Aliniaw), was introduced to the
market.8,9 Nitazoxanide is the first agent with proven efficacy in
cryptosporidiosis and has recently been approved in the USA for
the treatment of cryptosporidiosis and giardiasis in children and
adults.8 In comparison with metronidazole and other nitroimida-
zoles, nitazoxanide is well tolerated although mild to moderate
gastrointestinal disorders such as nausea and diarrhoea have
occasionally been associated with higher doses particularly used
in immunocompromised persons. However, these side effects are
rarely severe and do not require interruption of treatment.
Originally developed as a veterinary antihelminthic, nitazoxa-
nide is known to exhibit a broad spectrum of activity against
a wide variety of intestinal parasites such as G. lamblia,
Entamoeba histolytica10 the apicomplexan Cryptosporidium
parvum and enteric bacteria infecting animals and humans.11,12
Nitazoxanide is a nitrothiazolyl-salicylamide, which is well
absorbed after oral administration. Upon oral uptake, the drug is
rapidly deacetylated to tizoxanide and further metabolized to
tizoxanide-glucuronide.8 Tizoxanide has been reported to
display antimicrobial activity similar to nitazoxanide, while
tizoxanide-glucuronide was largely inactive against a number of
pathogens. Tizoxanide and tizoxanide-glucuronide are further
metabolized, or excreted, in urine and/or bile and faeces.
Nitazoxanide represents the parent compound of a class of
drugs named thiazolides.9 Thiazolides lacking the nitro group have
been shown to exhibit decreased efficacy against Giardia.10,13
Therefore, an involvement of the nitro group in the mechanism
of action, with the participation of POR similar to metronida-
zole, was postulated.14 The nitro group is also required for
in vitro activity against anaerobic bacteria.15 Inhibition of the
anaerobic energy metabolism through nitazoxanide by interfer-
ing in functional activity of POR has recently been reported for
other protozoan parasites,16 but this process is thought to be
only one of several pathways by which the drug exhibits antipro-
tozoal activity.8 In fact, more recent studies have shown that
nitazoxanide derivatives lacking the nitro group exhibit profound
in vitro activity against intracellular pathogens such as Neospora
caninum, C. parvum and Besnoitia besnoiti,9,17 suggesting that
the nitro group is not required for the activity against intracel-
lular parasites.
In a previous study, we investigated the in vitro effects of
nitazoxanide and other thiazolides against G. lamblia tropho-
zoites grown either axenically or in co-culture with Caco2
cells13 and have seen differences in the effects of metronidazole
and nitazoxanide on cellular morphology. In order to elucidate
the biochemical nature of resistance formation against nitazoxa-
nide and metronidazole, we have now generated metronidazole-
and nitazoxanide-resistant clones and compared them with the
wild-type WB C6 with respect to their growth behaviour and to
the expression pattern of genes that are potentially involved in
resistance formation. Besides the two POR genes found in the
Giardia genome (The Giardia lamblia Genome Database; www.
mbl.edu/Giardia) and a nitroreductase (NR) that binds to, and is
functionally inhibited by nitazoxanide and other thiazolides
(J. Mu¨ller, S. Sanderson, J. Wastling, N. Mu¨ller and
A. Hemphill, unpublished results), we have included two protein
disulphide isomerases (PDIs) expressed in trophozoites, namely
PDI2 and PDI4.18 PDIs were included in this analysis since in
N. caninum, PDI has been identified as a tizoxanide binding
protein and since recombinant PDI could be inhibited by various
thiazolides in vitro (J. Mu¨ller, A. Naguleswaran, N. Mu¨ller and
A. Hemphill, unpublished results). Furthermore, since upon
selective immunological and/or physiological pressure,
G. lamblia trophozoite populations may undergo antigenic vari-
ation19,20 and/or initiate encystations,21 variant surface protein
(VSP) and cyst wall protein (CWP) gene expression have also
been analysed in this study.
Materials and methods
Tissue culture media, biochemicals and drugs
If not otherwise stated, all biochemical reagents were from Sigma
(St Louis, MO, USA). Tizoxanide was synthesized at the Depart-
ment of Chemistry, University of Liverpool (A. Stachulski), nitazox-
anide at the Department of Chemistry and Biochemistry, University
of Berne (Ch. Leumann). For structural formulae, see Mu¨ller et al.13
They were kept as 100 mM stock solutions in DMSO at 48C.
Axenic culture of Giardia trophozoites and
drug treatment assays
Trophozoites from G. lamblia WB clone C6 were grown under
anaerobic conditions in 10 mL culture tubes (Nunc, Roskilde,
Denmark) containing modified TYI-S-33 medium as described.13 In
order to initiate subcultures, cultures with confluent trophozoite
lawns were incubated on ice for 15 min. Suspended living (adherent)
trophozoites were counted (Neubauer chamber, 200). Subcultures
were initiated by adding 104 trophozoites to a new culture tube.
The effects of drugs were assayed by adding increasing concen-
trations of nitazoxanide or metronidazole to trophozoite subcultures.
Proliferation was monitored by counting living trophozoites after
harvest at various time points. For this harvest, medium was
removed and replaced with ice-cold PBS in order to count only
living (adherent) trophozoites. IC50 values were obtained from
suitable fittings of the growth curves.13
Generation of nitazoxanide- and metronidazole-resistant
G. lamblia trophozoites
Nitazoxanide- and metronidazole-resistant G. lamblia trophozoites
were generated using parasites with the same genetic background
(i.e. WB C6). In order to obtain drug-resistant trophozoites,22
G. lamblia WB C6 wild-type parasites grown to confluence were
initially cultured in the presence of sublethal concentrations of the
two compounds (5 mM nitazoxanide or 10 mM metronidazole,
respectively). After 3 days, the medium was removed, viable tropho-
zoites remained attached to the tube walls, and fresh medium was
added, containing 7.5 mM nitazoxanide or 15 mM metronidazole,
respectively. The status of the trophozoites was monitored micro-
scopically by counting living trophozoites. When the respective
numbers remained constant or increased, fresh medium was added,
containing similar or slightly higher concentrations of the two
drugs. In case the number of living trophozoites decreased, medium
was replaced by fresh medium without the corresponding drug.23
This operation was repeated until levels of 40 mM nitazoxanide or
60 mM metronidazole were reached (Table 1). Clones from resistant
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cell lines were generated by two rounds of dilution of trophozoites
in drug-free medium and transfer to 96-well plates with an expec-
tance value (l) of 0.5 trophozoites per well according to the
Poisson law Pl(n) ¼ ln/n!  e2l, n being the number of events and
Pl(n) being the probability for n to occur with an expectance value
l. The plates were incubated in an anaerobic incubator (Scholzen
Microbiology Systems, Kriems, Switzerland) containing 100% N2
for 2 days. Wells were then screened for growing trophozoites and
the contents of 10 wells with growing trophozoites for each drug
resistance were then transferred to normal culture tubes containing
drug-free medium and allowed to recover for 1 day. Then, drugs
were added (40 mM nitazoxanide and 60 mM metronidazole,
respectively). The clones having maintained their resistance (four in
the case of nitazoxanide and six in the case of metronidazole) were
subcultivated. The clones with the best growth, i.e. the
nitazoxanide-resistant clone C4 and the metronidazole-resistant
clone C5, were selected for detailed characterization.
Processing of RNA samples and quantitative RT–PCR
To quantify gene expression by real-time RT–PCR, trophozoites of
WB C6 wild-type, clones C4 and C5 were grown in the absence of
drugs until near confluence was reached. Cells were harvested as
described and RNA was extracted using the Qiagen RNeasyTM kit
and including a DNase I digestion (to remove residual genomic
DNA) according to the manufacturer’s instructions. RNA was eluted
with 50 mL RNase-free water and stored at 2808C.
First strand cDNA was synthesized using the Qiagen
OmniscriptTM RT kit as described by the manufacturer with random
primers for subsequent ACT-, CWP1-, GDH-, NR-, PDI2-,
PDI4,- POR1-, POR4- and 16S rRNA-PCR or with a polyT-ANC
primer24 for subsequent VSPtot-, TSA417- and ACT-PCR (for
primer sequences, see Table 2). Overall amplifications of cDNA
molecules representing analogues of mRNA from different VSP
genes (VSPtot) were performed by 30 RACE PCR as previously
described.24 Briefly, amplification reaction mixes included a forward
primer (primer VSPtot) complementary to a highly conserved VSP
gene region (MM16 region, as described previously;25 see Table 2)
and a reverse anchor (ANC) primer (Table 2).24 Quantitative PCR
was done with 4 mL of 1:100-diluted cDNA using the Quanti
TectTM SYBR Green PCR Kit (Qiagen) in a 10 mL standard reaction
containing a 0.5 mM concentration of forward and reverse primers
(MWG Biotech, Ebersberg, Germany). Furthermore, a control PCR
included RNA equivalents from samples that had not been reverse
transcribed into cDNA (data not shown) to confirm that no DNA
was amplified from any residual genomic DNA that might have
resisted DNase I digestion (see above). PCR was started by initiating
the ‘Hot-Start’ Taq DNA polymerase reaction at 958C (15 min).
Subsequent DNA amplification was done in 40 cycles including
denaturation (948C, 15 s), annealing (608C, 30 s) and extension
(728C, 30 s); temperature transition rates in all cycle steps were
208C/s. Fluorescence was measured at 828C with primers for ACT-,
CWP1-, GDH-, NR-, PDI2-, PDI4,- POR1-, POR2- and 16S
rRNA-PCR or 798C for VSPtot-and TSA417-PCR during the temp-
erature shift after each annealing phase. From the quantitative RT–
PCR, mean values (+SE) from triplicate determinations were
assessed and expression levels of the genes summarized in Table 2
were given as values in arbitrary units relative to the amount of 16S
rRNA (for mRNA representing ACT, CWP1, GDH, NR, PDI2,
PDI4, POR1 and POR2) or the constitutively expressed ‘house
keeping’ gene ACT (for mRNA representing VSPtot and TSA417).
Cloning and heterologous expression of
G. lamblia PDI2 and PDI4
In order to clone GlPDI2 and GlPDI4 into the His-tag-expression
vector pET151 directional TOPO (Invitrogen, Carlsbad, Canada),
primers were created for the amplification of gene fragments encod-
ing the PDI polypeptides without signal peptides (Table 2). CACC
at the 50 end was added in order to allow directional cloning (MWG
Biotech, Ebersberg, Germany).
For amplification by PCR, DNA was extracted from 106 tropho-
zoites using the DNeasyTM kit (Qiagen, Hilden, Germany) accord-
ing to the manufacturer’s instructions and eluted from the spin
column with 50 mL ultrapure water. The PCR was performed using
0.6 U of Pfu (Promega, Madison, WI, USA), 2 mL of Pfu buffer
10 (Promega), 20 pmol of each primer, 0.16 mM dNTPs
(Promega) and 0.1–1 mL of DNA diluted 1/10 in a total volume of
20 mL. The amplification was performed at 568C (PDI2) or 548C
(PDI4) annealing temperature during 28 cycles in a GeneAmpTM
PCR System 9700 thermocycler (Applied Biosystems, Foster City,
CA, USA). The resulting products were inserted into pET151 using
the respective cloning kit according to the manufacturer’s instruc-
tions. The vector was transformed into Escherichia coli TOP 10
cells (Invitrogen).
For heterologous expression of recombinant PDIs, miniprep
DNA from E. coli TOP 10 containing the plasmid with the insert in
correct orientation was batch transformed into E. coli BL21 Star
(Invitrogen). The batch was grown overnight in 2 mL of LB with
100 ppm carbenicillin, then transferred to a 500 mL Erlenmeyer
containing 50 mL of LB with 100 ppm carbenicillin and grown until
A600 0.5 was reached. Expression of recombinant PDIs was induced
by addition of 1 mM IPTG. As a negative control, 10 mL of culture
Table 1. Schedule for the establishment of nitazoxanide (NTZ)-
and metronidazole (MET)-resistant G. lamblia WB C6 lines prior to
cloning (at the indicated time points, trophozoite medium was
replaced with new medium containing NTZ or MET as indicated)
Time (days) NTZ (mM) MET (mM)
0 5 10
3 7.5 15
5 7.5 15
10 10 20
12 10 20
14 10 20
17 15 30
19 0 30
21 10 40
24 15 40
27 20 50
30 20 50
34 25 60
37 25 60
41 transformation into stabilates, storage
in liquid nitrogen
Recovery
0 0 0
1 20 50
6 25 50
10 25 50
14 40 60
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was withdrawn prior to induction and cultivated in a 100 mL
Erlenmeyer. Cells were harvested after 3.5 h, chilled down, pelleted
by centrifugation (4000 g, 20 min, 48C) and stored at –208C.
For His-tag purification, pellets from induced E. coli cells were
suspended in 0.5 mL of 1 LEW buffer (Macherey-Nagel, Du¨ren,
Germany) containing 0.5% Triton X-100 and 10 mL of protease
inhibitor cocktail suitable for His-tag purification (Sigma P8849).
The suspension was freeze-thawed three times on dry ice, then cen-
trifuged for 15 min at 13 000 g and 48C. The extraction was
repeated once. Supernatants were combined and loaded on Protino
Ni-TED 150 columns (Macherey-Nagel) in tandem. Columns were
washed with 1 LEW buffer, proteins were eluted with elution
buffer according to the manufacturer’s instructions. Eluted protein
was stored in 50% glycerol at 2208C.
PDI enzyme assay
PDI activity was measured by a turbidimetric assay based on the
polymerization of reduced insulin.18,26,27 The assay was performed
in 96-well microtitre plates (Nunc). Per well, 80 mL of assay buffer
(potassium phosphate 100 mM, pH 7.0) was mixed with 10 mL of
bovine pancreas insulin (1.6 mM, dissolved in 0.1 M HCl) and
enzymes (0–5 mL) or buffer (substrate blank). The reaction was
started by addition of 5 mL of dithiothreitol (20 mM in assay
buffer). After 2 min of preincubation, absorbance at 630 nm was
read at various time points (0–20 min) on a 96-well plate reader
(MRXII, Dynex, Chantilly, VA, USA). Enzyme activity was calcu-
lated from the linear increase in turbidity over time.
Results
Generation of nitazoxanide- and metronidazole-resistant
G. lamblia trophozoites
By axenic culture of G. lamblia WB C6 trophozoites in the pre-
sence of slowly and continuously increasing concentrations of
nitazoxanide and metronidazole, respectively (Table 1), two
drug-resistant trophozoite lines were generated, transformed into
stabilates, stored in liquid nitrogen and subsequently recovered
in trophozoite medium. These trophozoite lines were subcultured
in the presence of up to 40 mM nitazoxanide and 60 mM metro-
nidazole, respectively. Clones from resistant cell lines were gen-
erated and growth of the nitazoxanide-resistant clone C4 and the
metronidazole-resistant clone C5 was tested on normal medium.
All three clones reached comparable densities at 4 days after
inoculation, C5 started however, with a delay (Figure 1). Upon
prolonged growth in drug-free medium for more than 10 gener-
ations, resistance was maintained. The clones C4 and C5
encysted as well as the wild-type when put on encystation
medium (data not shown).
Table 2. Overview of primers used in this study
Gene
Accession number
Region of CDS or
rRNA Primer (50 ! 30)
Actin (ACT)
EAA39190
CDS 715–933 ACTquantF ACATATGAGCTGCCAGATGG
ACTquantR TCGGGGAGGCCTGCAAAC
Cyst wall protein 1 (CWP1)
XM 766142.1
CDS 367–713 CWP1quantF GGCGATATTCCCGAGTGCATGTG
CWP1quantR GTGAGGCAGTACTCTCCGCAGT
Glutamate dehydrogenase (GDH)
XM_773614
CDS 761–893 GDHquantF AGGTCCTCACCTTCTCAGACT
GDHquantR GGATACTTGTCCTTGAACTCGG
Nitroreductase (NR)
EAA43030.1
CDS 526–794 plus 8 of 30 utr. NRquantF CCTGCTGACAAGGCCGCA
NRquantR AACACCAATTACTTAAATGTAATG
Protein disulphide isomerase 2 (PDI2)
EAA42483.1
CDS 1055–1350 plus 13 of 30 utr.
CDS 57–1350 plus 12 of 30 utr.
PDI2quantF GGCCCAGGGCGAGGAGT
PDI2quantR AGACAAGAACCGTTTACTTCTT
PDI2fullF CACCTTGGTTCTCACGCAAGACA
PDI2fullR GACAAGAACCGTTTACTTCT
Protein disulphide isomerase 4 (PDI4)
AF295634.1
CDS 46–1065
CDS 775–1065 plus 1 of 30 utr.
PDI4fullF CACCGAGGTGCTCGTTCTCCA
PDI4fullR TCAGAGCTCCTTGTCCCC
PDI4quantF CCGAAGGACGAGACTTCCT
PDI4quantR CTCAGAGCTCCTTGTCCCC
Pyruvate oxidoreductase 1 (POR1)
Giardia DB orf:17063
CDS 3341–3600 plus 9 of 30 utr. POR1quantF ATCCAACGCGACCCAGAAG
POR1quantR GTTCACTGCTTACTCCGCC
Pyruvate oxidoreductase 2 (POR2)
Giardia DB orf:114609
CDS 3325–3547 POR2quantF CTCGCACATGGTCCAGGG
POR2quantR AGAGCCGCAGCCATCTCC
Ribosomal RNA 16S (16S rRNA)
M54878.1
CDS 79–300 Gl16SquantF GACGGCTCAGGACAACGG
Gl16SquantR CTCTCCGGAGTCGAACCC
Variant surface protein TSA417
U89152.1
CDS 127–335 TSA417quantF TGTGGAACGTGTGCCAATAG
TSA417quantR AGACACGTAGTACAGTCGG
Variant surface protein (total) see Von Allmen et al.24 VSPtotquantF (MM16) GGCTTCCTCTGCTGGTGGTTC
VSPtotquantR (ANC) GACCACGCGTATCGATGTCGA
CDS, coding sequence; utr., untranslated.
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Cross-resistance
In order to determine IC50 values of the resistant clones C4 and
C5 in the presence of nitazoxanide and metronidazole, tropho-
zoites of the respective strains were grown for 4 days at various
drug concentrations. The nitazoxanide-resistant clone C4 exhib-
ited cross-resistance to metronidazole with IC50 values of
37 mM for nitazoxanide and 59 mM for metronidazole, whereas
the metronidazole-resistant clone C5 was resistant to metronida-
zole only (IC50 42.5 mM) while no resistance to nitazoxanide
was noted (IC50 3.6 mM) (Figure 2). The IC50 values for the
wild-type WB C6 were 1.8 mM for nitazoxanide and 8.1 mM for
metronidazole as estimated after logarithmic transformation of
the curves shown in Figure 2.
In order to investigate whether resistance formation in the
case of the clone C4 was a multidrug resistance phenomenon,
C4 and wild-type cells were grown in the presence of non-nitro
drugs, namely albendazole and the isoflavonoids genistein, daid-
zein and formononetin, all described as powerful antigiardial
agents.28,29 Both wild-type and C4 trophozoites were equally
sensitive to these compounds (growth curves not shown).
Gene expression
In order to quantify expression potentially involved in resistance
formation, we developed a quantitative real-time RT–PCR assay
using reverse transcripts of 16S rRNA as reference for the
amount of total cDNA. The gene expression level of actin
(ACT) was not affected in the clones C4 and C5 as compared
with the wild-type. Interestingly, gene expression levels of gluta-
mate dehydrogenase (GDH) were decreased to 37% of the wild-
type levels in clone C4 and to 59% in clone C5. As a marker for
encystation-related genes, we investigated ‘background’ CWP1
gene expression in trophozoites. Surprisingly, expression was
decreased to 44% of wild-type levels in both strains (Figure 3).
POR is encoded by two genes in the Giardia genome,
namely POR1 and POR2. In wild-type trophozoites, POR2 had
7.2-fold higher gene expression levels than POR1. In the clone
C5, expression of both genes was slightly decreased to 68 (POR1)
and 66% (POR2) of their respective wild-type levels (Figure 3).
Expression of a Giardia NR was assessed in wild-type versus
resistant parasites. This enzyme had expression levels one
Figure 1. Growth of G. lamblia WB C6 wild-type (wt), nitazoxanide-
resistant (NTZr C4) and metronidazole-resistant (METr C5) trophozoites.
At day 0, 104 trophozoites were inoculated to normal culture medium.
Trophozoite numbers per culture tube are given as mean values (+SE) from
quadruplicate determinations.
Figure 2. Trophozoite numbers in the presence of metronidazole (MET) or
nitazoxanide (NTZ). At day 0, 104 trophozoites of G. lamblia WBC6
wild-type (wt), nitazoxanide-resistant (NTZr C4) and metronidazole-resistant
(METr C5) were inoculated to culture medium containing increasing
amounts of nitazoxanide (white symbols) or metronidazole (black symbols).
Trophozoites were harvested at day 4 after inoculation. Trophozoite numbers
are given as mean values (+SE) from quadruplicate determinations.
Figure 3. Quantification of gene expression by RT–PCR. Trophozoites were
grown in normal culture medium until near confluency was reached. RNA
was extracted and reverse transcribed to cDNA. Transcripts of actin (ACT),
glutamate dehydrogenase (GDH) and pyruvate oxidoreductase (POR1 and 2),
nitroreductase (NR), protein disulphide isomerase (PDI2 and 4) and cyst wall
protein (CWP1) were quantified in relation to 16S rRNA. Amounts are
expressed in arbitrary units (AU). Mean values (+SE) for triplicates are
given. Note that for reasons of scale, GDH and CWP1 values are multiplied
by 0.1, NR and PDI4 values by 10 and PDI2 values by 1000. wt, wild-type.
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magnitude lower than the POR genes and the ACT gene. In the
clones C4 and C5, NR expression levels were only slightly
decreased (69% of wild-type level in C4 and 78% of wild-type
level in C5; Figure 3).
In addition, we analysed expression levels of PDI2 and PDI4,
two major PDIs in Giardia. The expression level of PDI2 was
approximately three magnitudes lower than the actin expression
level. PDI2 gene expression was significantly increased in both
resistant clones (230% of wild-type level in clone C4 and 255%
in clone C5) PDI4 exhibited two magnitudes higher gene
expression levels as compared with PDI2. In the
nitazoxanide-resistant clone C4, PDI4 gene expression was
increased to nearly twice the wild-type levels, whereas in the
metronidazole-resistant clone C5, PDI4 gene expression levels
remained nearly unchanged (Figure 3).
Recombinant PDI is inhibited by nitazoxanide
When subjected to a PDI enzyme assay based on the polymeriz-
ation of reduced insulin, bacterially expressed and purified
recPDI4 was shown to be functionally active and catalysed the
cross-linking of insulin monomers. Classical PDI inhibitors like
bacitracin30 and para-chloro-mercuri benzoic acid (PCMBA)
readily inhibited the activity of the recPDI4. Interestingly, also
nitazoxanide and tizoxanide, but not metronidazole, inhibited
recPDI4 activity (Figure 4). Similar results were obtained with
using recPDI2 where 50 mM nitazoxanide and tizoxanide showed
inhibition to ,20% of the control levels (data not shown).
VSP gene expression is strongly affected in nitazoxanide-
and metronidazole-resistant G. lamblia clones
The most dramatic differences between wild-type and resistant
G. lamblia clones were found when expression of VSP genes
was investigated. For respective analyses, cDNA was synthesized
issuing from polyT-ANC primers instead of random oligo
primers (see the Materials and methods section). This
experimental strategy allowed RT–PCRs to be performed with a
general forward primer (MM16 primer) targeted to a highly con-
served VSP gene region and a reverse primer targeted to the 30
terminal ANC sequence adjacent to the polyT stretch of the
cDNA molecules (Figure 5). By comparative quantitative RT–
PCR, the cDNA synthesized with polyT-ANC was also ampli-
fied by including a primer pair specific for the gene TSA417
that encodes the major VSP in WB C6 (Figure 5). Values from
both PCRs were determined relative to the ACT gene
expression, which was shown to be constant in wild-type and
resistant strains (Figure 3). While wild-type clone WB C6 exhib-
ited TSA417 gene expression, corresponding expression levels
were dramatically reduced and virtually non-detectable in resist-
ant clones C4 and C5. Conversely, the overall expression of
VSP genes (VSPtot) remained constant, suggesting that resistance
was associated with an antigenic switch from TSA417 to one, or
several unknown VSPs (Figure 5).
Discussion
Our present investigations have demonstrated that giardial resist-
ance to nitazoxanide can be triggered in vitro, and that nitazoxa-
nide resistance formation resulted in a simultaneous increase of
resistance to metronidazole. Conversely, in vitro generated
metronidazole resistance turned out to mediate no ‘cross-
resistance’ to nitazoxanide. In particular, we have been success-
ful in generating in vitro the nitazoxanide-resistant clone C4 and
the metronidazole-resistant clone C5 of G. lamblia WB C6. The
two clones do not exhibit the same resistance pattern since C4 is
cross-resistant to metronidazole, whereas C5 is sensitive to nita-
zoxanide. This latter finding is in agreement with observations
in Helicobacter pylori where nitazoxanide-resistant strains did
Figure 4. PDI activity assay based on the reduction and polymerization of
insulin with recombinant PDI4. Inhibition test with known PDI inhibitors,
namely bacitracin (BAC; 3 mM) and para-chloro-mercuri benzoic acid
(PCMBA; 0.1 mM), metronidazole (MET; 50 mM), nitazoxanide (NTZ;
50 mM) and tizoxanide (TIZ; 50 and 100 mM). Assays were run in triplicate.
Bars correspond to mean values (+SE).
Figure 5. Quantification of variant surface protein (VSP) gene expression
by real-time RT–PCR. Trophozoites were grown in normal culture medium
until near confluence was reached. RNA was extracted and reverse
transcribed to cDNA. Transcripts of the VSP gene encoding TSA417 and
total VSPs (VSPtot) were quantified in relation to actin cDNA. Amounts are
expressed in arbitrary units (AU). Mean values (+SE) for triplicate
determinations are given. wt, wild-type; NTZr, nitazoxanide-resistant;
METr, metronidazole-resistant.
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not exhibit cross-resistance to metronidazole.23 To our knowl-
edge, clinically relevant resistance to nitazoxanide has never
been reported to date, either in H. pylori,31 Giardia or in
Cryptosporidium,8,12 while metronidazole-resistant isolates of
H. pylori and G. lamblia have been obtained from infected
patients.31
Although nitazoxanide and metronidazole exhibit structural
similarities, the two compounds differentially affect Giardia in
terms of morphological alterations.13 In addition, the differences
in respective resistance patterns as outlined above suggest differ-
ences in their mode of action. Earlier findings had demonstrated
that reduction of the nitro group is crucial for metronidazole
activation,7 since oxidoreductases such as POR or other NRs
that are present in anaerobic or microaerophilic microorganisms
will convert the nitro group into a toxic radical. In addition, in
these organisms, resistance to metronidazole was associated with
the functional inhibition of POR activity.3,4,32,33
While it has been recently shown that nitazoxanide and tizox-
anide both inhibit the POR activities in Giardia, Trichomonas,
Entamoeba and several anaerobic bacteria,16 there is no evi-
dence that the thiazole-associated nitro group is actually reduced
upon treatment of these organisms. In fact, this study suggests
that unreduced nitazoxanide inhibits POR activity by interfering
with its cofactor thiamine pyrophosphate.16 In any case, the pre-
sence of the nitro group was also found to be crucial for the
antigiardial activity of several nitro-thiazolides with low inhibi-
tory constants.13
Taking these findings into account, we decided to perform an
RT–PCR-based investigation to assess the POR gene expression
levels in the resistant clones C4 and C5. Here, the
nitazoxanide-resistant clone C4 did not exhibit significant
reduction of expression of the two POR genes, POR1 and
POR2, but clearly expression levels were reduced in the
metronidazole-resistant clone C5 (Figure 3). This indicates that
metronidazole resistance formation may occur in at least two
different manners including either reduction of POR gene
expression or an as yet unknown pathway that does not depend
on an alteration of the respective enzymatic activity.
Additional investigations on the expression of NR, another
enzyme potentially involved in nitro reduction (Figure 3), show
that both giardial nitazoxanide and metronidazole resistance for-
mation do not lead to significant alterations in NR gene
expression. NR has been recently isolated from Giardia by affinity
chromatography using tizoxanide-epoxy-agarose affinity chromato-
graphy, it was shown to bind to nitazoxanide and tizoxanide, and
these two compounds and series of other nitro-thiazolides were
shown to inhibit the functional activity of recombinant NR in vitro
(J. Mu¨ller, S. Sanderson, J. Wastling, N. Mu¨ller and A. Hemphill,
unpublished results). Conversely, transcript levels of the highly
expressed GDH gene were significantly lowered in both resistant
strains. On the metabolic level, this down-regulation of GDH
could lead to a reduction of the electron flow to NAD(P)H and
thus ultimately to potential reducers of the nitro group from
nitazoxanide and/or metronidazole, respectively. If the GDH-
dependent redox pathway was in fact involved in activation of the
two nitro compounds, down-regulation of GDH or related genes
would be an obvious mechanism to mediate nitazoxanide and/or
metronidazole resistance formation in Giardia.
Further analysis of gene expression levels of PDI2 and PDI4
resulted in the intriguing findings that PDI2 expression levels
were increased in both clones, C4 and C5, and PDI4 transcript
levels were higher in clone C4 (Figure 3). Further, we found that
nitazoxanide and tizoxanide both inhibited the functional activi-
ties of PDI2 and PDI4 (see Figure 4). These observations
demonstrated that nitazoxanide interferes with PDI functions,
and also suggested that up-regulation of PDI expression during
resistance formation may compensate for nitazoxanide-mediated
loss of PDI activity. PDIs have to be considered as potential
targets for antigiardial drug treatment since they are ubiquitous
and important players in the maintenance of the cellular redox
status by refolding proteins through the rearrangement of disul-
phide bridges.34–36 While, as described above, the nitazoxanide-
and metronidazole-resistant strains differ from their isogenic
wild-type WB C6 with respect to the expression patterns of
genes encoding metabolic enzymes (GDH, POR2, PDI1 and
PDI2), it is important to note that the by far most drastic regulat-
ory effect was observed for the TSA417 gene locus, encoding
the major surface antigen (VSP C6) of WB C6. Expression of
TSA417 was massively down-regulated in both resistant strains.
As shown in our previous work, G. lamblia is able to escape
host defence mechanisms by changing the expression of its
surface antigens.19,20 The phenomenon of antigenic variation
indicates that G. lamblia has adopted the capability to alter its
gene expression profile in response to an environmental pressure.
As reported recently, epigenetic mechanisms probably including
gene acetylation seem to be responsible for antigenic variation.37
Similar adaptive gene-regulatory processes may cause pleiotro-
pic effects that mediate, or at least participate in, antigiardial
drug resistance formation. This adaptive mechanism may
include up-, or down-regulation, of the expression of proteins
involved in drug interaction, or of genes having direct, or indir-
ect, effects on components involved in the mode of action of the
drugs. In future, we will apply various genomic and proteomic
approaches to assess the complexity of those cellular functions
that are possibly involved in (multi-) drug resistance formation
of the parasite.
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